Sign in
CompletedPhase 2

Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury

Key facts

Who runs it
Hospital Civil de Guadalajara
Where
Mexico2 sites in 1 countryChoose a country to see its locations
Trial code
Status
Completed
Phase
Phase 2
People taking part
120 people enrolled
Started
6 Jan 2023
Ended
30 Sept 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Iron dextran
  • Placebo
Record updated
1 October 2024

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Hospitalized patients with acute kidney injury
  • iron levels <13 μmol/L or a transferrin saturation <20%

Who cannot take part

  • kidney transplant
  • received any red blood cell transfusion before randomization
  • Chronic Kidney Disease grade 5
  • less than 18 years old
  • AKI within the past three months
  • chronic dialysis
  • hospital stay less tahn 48 hours
  • missing data that would render analysis incomplete

Where is this trial?

It has locations in one country. Choose a country to see its locations.

What happens in this trial

What the trial wants to find out

This clinical trial aims to carry out research on the effect on hemoglobin and renal function of intravenous administration of iron dextran as a repletion strategy in patients with iron deficiency anemia and acute kidney injury, in which the patient may benefit from this drug as it is expected to correct anemia, ferropenia and renal function parameters, when compared with a control group (placebo), the safety of the drug will also be assessed by recording adverse effects.

Read full original descriptionShow less

The investigators will point out with the patient the risks and benefits of their inclusion in this type of study and the investigators will attend to all the doubts that are generated, as well as immediately report to the research ethics committee any serious adverse effects. The results will be presented at national and international conferences and will be published in high-impact journals, and will also be the subject of a thesis to achieve the title of specialist.

The 2 groups in the trial

  • Iron dextran IVTreatment being tested

    In patients with acute renal damage, they will be aleatorized to receive the administration of intravenous iron dextran 1200mg in 1 single exhibition compared to placebo.

    Treatment: Iron dextran

  • PlaceboPlacebo, for comparison

    In patients with acute renal damage, they will be aleatorized to receive the administration of placebo.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Intravenous Iron Repletion on Renal Function in Patients With Iron Deficiency and Acute Kidney Injury, Clinical Trial
Publications
Record updated
1 October 2024